Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project

• Published in: Alzheimer's research & therapy Vol. 11; no. 1; p. 33
• Main Authors: van Maurik, Ingrid S, Slot, Rosalinde E R, Verfaillie, Sander C J, Zwan, Marissa D, Bouwman, Femke H, Prins, Niels D, Teunissen, Charlotte E, Scheltens, Philip, Barkhof, Frederik, Wattjes, Mike P, Molinuevo, Jose Luis, Rami, Lorena, Wolfsgruber, Steffen, Peters, Oliver, Jessen, Frank, Berkhof, Johannes, van der Flier, Wiesje M
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.04.2019; BioMed Central; BMC
• Subjects: Aged; Aging; Alzheimer's disease; Atrophy; Biological markers; Biomarkers; Biomarkers - cerebrospinal fluid; Brain - diagnostic imaging; Brain research; Caregivers; Cerebrospinal fluid; Cognitive ability; Cognitive disorders; Cognitive Dysfunction - cerebrospinal fluid; Cognitive Dysfunction - diagnosis; Cognitive Dysfunction - diagnostic imaging; Dementia; Dementia - cerebrospinal fluid; Dementia - diagnosis; Dementia - diagnostic imaging; Development and progression; Diagnostic imaging; Disease Progression; Female; Humans; Magnetic resonance imaging; Male; Medical imaging equipment; Medical prognosis; Memory; Middle Aged; Neurology; NMR; Nuclear magnetic resonance; Pathology; Patients; Precision Medicine; Progression; Risk Factors; Progression; Biomarkers; Cerebrospinal fluid; Magnetic resonance imaging

Biomarkers such as cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) have predictive value for progression to dementia in patients with mild cognitive impairment (MCI). The pre-dementia stage takes far longer, and the interpretation of biomarker findings is particular relevant for indiv...